IPHA

Innate Pharma ADR

Sep 22 • 02:35PM ET

1.85

-0.02 -1.07 %

Healthcare • Biotechnology • France • NASD

Peers: BPMC FATE AFMD NKTR PDSB ONCT CTMX IMTX IMUX SWTX

Index	-	P/E	-	EPS (ttm)	-0.60	Insider Own	-	Shs Outstand	92.16M	Perf Week	-10.89%
Market Cap	170.50M	Forward P/E	-	EPS next Y	-0.63	Insider Trans	-	Shs Float	-	Perf Month	-17.04%
Enterprise Value	131.77M	PEG	-	EPS next Q	-0.14	Inst Own	0.11%	Short Float	-	Perf Quarter	2.78%
Income	-50.06M	P/S	26.19	EPS this Y	4.05%	Inst Trans	0.68%	Short Ratio	4.01	Perf Half Y	-7.27%
Sales	6.51M	P/B	28.24	EPS next Y	0.00%	ROA	-36.88%	Short Interest	0.05M	Perf YTD	0.54%
Book/sh	0.07	P/C	2.42	EPS next 5Y	3.47%	ROE	-271.32%	52W High	3.51 -47.30%	Perf Year	-16.29%
Cash/sh	0.76	P/FCF	-	EPS past 3/5Y	5.60% -13.71%	ROIC	-183.50%	52W Low	1.29 43.41%	Perf 3Y	-26.85%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-1.57% -29.28%	Gross Margin	-	Volatility	6.50% 5.21%	Perf 5Y	-70.21%
Dividend TTM	-	EV/Sales	20.24	EPS Y/Y TTM	-31.24%	Oper. Margin	-957.33%	ATR (14)	0.12	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.21	Sales Y/Y TTM	-75.77%	Profit Margin	-768.78%	RSI (14)	33.51	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.21	EPS Q/Q	19.00%	SMA20	-9.73%	Beta	0.04	Target Price	5.74
Payout	-	Debt/Eq	5.25	Sales Q/Q	-79.64%	SMA50	-10.36%	Rel Volume	1.13	Prev Close	1.87
Employees	181	LT Debt/Eq	3.52	Earnings	Sep 17 BMO	SMA200	-7.26%	Avg Volume	12.24K	Price	1.85
IPO	Oct 17, 2019	Option/Short	No / Yes	EPS/Sales Surpr.	9.80% -59.09%	Trades		Volume	10,999	Change	-1.07%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-18-25	Downgrade	Leerink Partners	Outperform → Market Perform
Sep-18-25	Downgrade	H.C. Wainwright	Buy → Neutral
Jul-28-25	Initiated	BTIG Research	Buy	$8
Sep-03-21	Upgrade	SVB Leerink	Mkt Perform → Outperform	$7
Dec-15-20	Downgrade	SVB Leerink	Outperform → Mkt Perform	$7 → $5
Nov-24-20	Initiated	Goldman	Neutral	$4.75

Sep-18-25 09:38AM	Target initiated, Nike upgraded: Wall Street's top analyst calls (The Fly) -5.37%
03:00AM	Innate Pharma SA (IPHA) (H1 2025) Earnings Call Highlights: Strategic Focus and Financial ... (GuruFocus.com)
Sep-17-25 01:00AM	Innate Pharma Reports First Half 2025 Business Update and Financial Results (Business Wire)
Sep-16-25 09:15AM	Innate Pharma SA (IPHA) Q2 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Sep-15-25 01:00AM	Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event (Business Wire)
04:30AM	Loading…
Sep-10-25 04:30AM	Innate Pharma Announces Conference Call and Webcast for First Half 2025 Financial Results and Business Update (Business Wire)
Sep-02-25 01:00AM	Number of Shares and Voting Rights of Innate Pharma as of September 1, 2025 (Business Wire)
Aug-04-25 01:00AM	Number of Shares and Voting Rights of Innate Pharma as of August 1, 2025 (Business Wire)
Jul-29-25 01:00AM	Innate Pharma Announces Its Participation in the BTIG Virtual Biotechnology Conference (Business Wire)
Jul-04-25 01:00AM	Number of Shares and Voting Rights of Innate Pharma as of July 3, 2025 (Business Wire)
Jun-17-25 01:00AM	Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences (Business Wire)
Jun-13-25 01:00AM	Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress (Business Wire)
May-27-25 01:00AM	Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences (Business Wire)
May-23-25 01:00AM	Outcome of Innate Pharmas 2025 Annual General Meeting (Business Wire)
01:00AM	Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides (Business Wire)
01:00AM	Loading…
May-19-25 01:00AM	Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting (Business Wire)
May-15-25 01:00AM	Innate Pharma Highlights ANKET Abstracts Selected for the EHA 2025 Congress (Business Wire)
May-13-25 01:00AM	Innate Pharma Reports First Quarter 2025 Business Update and Financial Results (Business Wire) -12.07%
May-12-25 01:00AM	Number of Shares and Voting Rights of Innate Pharma as of May 5, 2025 (Business Wire)
May-06-25 01:00AM	Innate Pharma announces conference call and webcast for Q1 2025 business update (Business Wire)
Apr-30-25 11:30AM	Innate Pharma Files Its 2024 Universal Registration Document (Document denregistrement universel) and 2024 Annual Report on Form 20-F (Business Wire)
Apr-29-25 03:00PM	Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting (Business Wire) +5.26%
Apr-28-25 01:00AM	Number of Shares and Voting Rights of Innate Pharma as of April 25, 2025 (Business Wire) +5.56%
Apr-24-25 01:35AM	Innate Pharma Announces 15M Investment by Sanofi (Business Wire)
Apr-23-25 01:00AM	Innate Pharma Regains Its Rights on CD123 Targeting ANKET and Announces Sanofis Intention to Make a Strategic Investment in the Company (Business Wire)
Apr-16-25 01:00AM	Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025 (Business Wire)
01:00AM	Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition (Business Wire)
Apr-05-25 11:00AM	Markets Watch Out For Core CPI With Big Banks Set To Report Earnings (Seeking Alpha)
Apr-03-25 01:00AM	Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum (Business Wire) +7.26%
Mar-27-25 04:49PM	Innate Pharma S.A. (IPHA) Q4 2024 Earnings Call Transcript (SeekingAlpha) +8.84%
02:00AM	Loading…
02:00AM	Innate Pharma Reports Full Year 2024 Financial Results and Business Update (Business Wire)
Mar-26-25 02:00AM	Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting (Business Wire) -8.12%
Mar-25-25 02:00AM	Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference (Business Wire)
Mar-21-25 09:10AM	Innate Pharma: Moving Into The Padcev Space (SeekingAlpha)
Mar-20-25 02:00AM	Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results (Business Wire)
Feb-27-25 01:00AM	Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference (Business Wire)
Feb-17-25 01:02AM	Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Szary Syndrome (Business Wire)
Jan-27-25 01:00AM	Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors (Business Wire)
Jan-21-25 01:00AM	Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York (Business Wire)
Jan-16-25 01:00AM	Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024 (Business Wire)
Jan-10-25 01:00AM	Innate Pharma Announces Transformative Strategy to Accelerate Growth (Business Wire)
Dec-20-24 01:00AM	Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire) -5.09%
Dec-10-24 06:30AM	Innate Pharma SA Reveals Promising Lacutamab Trial Results (TipRanks) -5.26%
Dec-09-24 01:00AM	Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma (Business Wire) +29.25%
Dec-06-24 01:00AM	Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma (Business Wire)
Dec-03-24 01:00AM	Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024 (Business Wire)
Nov-20-24 01:00AM	Innate Pharma Releases Its 2025 Financial Calendar (Business Wire) +13.12%
Nov-19-24 01:00AM	Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET IPH6501 (Business Wire)
Nov-13-24 01:00AM	Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results (Business Wire) -11.82%
Nov-08-24 01:00AM	Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024 (Business Wire)
Nov-07-24 01:00AM	Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates (Business Wire) -10.45%
Oct-29-24 02:00AM	Innate Pharma Announces Its Participation in Upcoming Investor Conferences (Business Wire) +8.19%
Oct-14-24 01:00AM	Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board (Business Wire)
Sep-30-24 01:00AM	Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024 (Business Wire)
Sep-23-24 01:00AM	Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors (Business Wire)
Sep-12-24 01:00AM	Innate Pharma Reports First Half 2024 Business Update and Financial Results (Business Wire)
Sep-09-24 01:00AM	Innate Pharma SA:Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024 (Business Wire)
Sep-05-24 01:00AM	Innate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business Update (Business Wire)
Sep-04-24 01:00AM	Innate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-01-24 01:00AM	Innate Pharma Announces Its Participation in Upcoming Investor Conference (Business Wire)
Jul-25-24 01:00AM	Number of Shares and Voting Rights of Innate Pharma as of July 10, 2024 (Business Wire) -7.52%
Jun-18-24 01:00AM	Number of Shares and Voting Rights of Innate Pharma as of June 10, 2024 (Business Wire)
Jun-17-24 01:00AM	Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial (Business Wire) -10.64%
Jun-10-24 07:32AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) -6.92%
Jun-04-24 01:00AM	Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides (Business Wire) +5.26%
May-28-24 01:00AM	Innate Pharma Announces Its Participation in Upcoming Investor Conferences (Business Wire)
May-24-24 01:00AM	Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting (Business Wire)
May-23-24 04:00PM	Outcome of Innate Pharmas 2024 Annual General Meeting (Business Wire)
May-21-24 01:00AM	Innate Pharma: Clarification Regarding SAR443579 Designation (Business Wire)
May-15-24 01:00AM	Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress (Business Wire) -5.06%
May-14-24 01:00AM	Innate Pharma Reports First Quarter 2024 Business Update and Financial Results (Business Wire)
May-07-24 01:00AM	Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update (Business Wire)
Apr-15-24 01:00AM	Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024 (Business Wire)
01:00AM	Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients (Business Wire)
Apr-10-24 12:00PM	All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy (Zacks)
01:00AM	Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate (Business Wire)
Apr-09-24 01:00AM	Innate Pharma Announces Its Participation in Upcoming Investor Conference (Business Wire)
Apr-05-24 03:34AM	Innate Pharma Files Its 2023 Universal Registration Document (Document denregistrement Universel) and 2023 Annual Report on Form 20-F (Business Wire)
Mar-22-24 11:33AM	Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-21-24 02:00AM	Innate Pharma Reports Full Year 2023 Financial Results and Business Update (Business Wire)
Mar-19-24 02:00AM	Innate Pharma Announces Its Participation to Upcoming Investor Conference (Business Wire)
Mar-14-24 02:00AM	Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results (Business Wire)
Mar-06-24 01:00AM	Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkins Lymphoma (Business Wire)
01:00AM	Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024 (Business Wire)
Feb-21-24 01:00AM	Innate Pharma Announces Its Participation to Upcoming Investor Conference (Business Wire)
Jan-12-24 01:00AM	Number of Shares and Voting Rights of Innate Pharma as of January 1, 2024 (Business Wire)
Jan-04-24 01:00AM	Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program (Business Wire)
12:59AM	Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board (Business Wire)
Dec-19-23 01:00AM	Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi (Business Wire) +9.80%
Dec-18-23 01:00AM	Innate Pharma Announces Leadership Change (Business Wire)
Dec-11-23 01:00AM	Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023 (Business Wire) -5.43%
Dec-10-23 01:00AM	Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Szary Syndrome at ASH 2023 (Business Wire)
Nov-27-23 01:00AM	Innate Pharma to Host Virtual KOL Event on Lacutamab (Business Wire)
Nov-15-23 10:36AM	Innate Pharma S.A. (NASDAQ:IPHA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 01:00AM	Innate Pharma Reports Third Quarter 2023 Financial Results and Business Update (Business Wire) +13.66%
Nov-07-23 01:00AM	Innate Pharma Announces Conference Call for Third Quarter 2023 Business Update (Business Wire)
Nov-03-23 02:00AM	Innate Pharma Announces New Clinical Data for Lacutamab and SAR443579/IPH6101 at ASH 2023 (Business Wire) +18.39%
Oct-27-23 01:00AM	Innate Pharma Announces Its Participation to Upcoming Investor Conferences (Business Wire)
Oct-19-23 01:00AM	Innate Pharma 2024 Financial Calendar (Business Wire) -8.78%
Oct-16-23 01:00AM	Innate Pharma Announces Abstracts Selected for ESMO Congress 2023 (Business Wire)

Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Herve Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournie, and Francois Romagne on September 23, 1999 and is headquartered in Marseille, France.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Novo Nordisk A/S	10% Owner	May 30 '25	Proposed Sale	2.14	921,897	1,972,859		May 30 08:31 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IPHA

Innate Pharma ADR

Upgrade your FINVIZ experience